These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 15086832

  • 1. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y, Sakamoto M, Hata J, Yamada T.
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
    Wang M, Liu Y, Li Y, Wu H.
    Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV, Witzig TE.
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [Abstract] [Full Text] [Related]

  • 8. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [Abstract] [Full Text] [Related]

  • 9. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR.
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [Abstract] [Full Text] [Related]

  • 10. Thalidomide for the treatment of multiple myeloma.
    Hattori Y, Iguchi T.
    Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
    [Abstract] [Full Text] [Related]

  • 11. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
    McMeekin DS, Sill MW, Darcy KM, Stearns-Kurosawa DJ, Webster K, Waggoner S, Benbrook D.
    Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
    [Abstract] [Full Text] [Related]

  • 12. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.
    Kumar S, Witzig TE, Dispenzieri A, Lacy MQ, Wellik LE, Fonseca R, Lust JA, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV.
    Leukemia; 2004 Mar; 18(3):624-7. PubMed ID: 14749707
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Angiogenesis in multiple myeloma.
    Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O.
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [Abstract] [Full Text] [Related]

  • 17. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 18. Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors.
    Rana C, Sharma S, Agrawal V, Singh U.
    Ann Hematol; 2010 Aug; 89(8):789-94. PubMed ID: 20177896
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prognostic significance of vascular endothelial growth factor immunoexpression in the context of adverse standard prognostic factors in multiple myeloma.
    Ribas C, Colleoni GW, Silva MR, Carregoza MJ, Bordin JO.
    Eur J Haematol; 2004 Nov; 73(5):311-7. PubMed ID: 15458509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.